原研机构 |
非在研机构- |
权益机构- |
最高研发阶段批准上市 |
首次获批日期 中国 (2025-01-24), |
最高研发阶段(中国)批准上市 |
特殊审评- |
开始日期2025-07-30 |
申办/合作机构 |
开始日期2025-03-31 |
申办/合作机构 |
开始日期2025-03-25 |
申办/合作机构 |
适应症 | 国家/地区 | 公司 | 日期 |
---|---|---|---|
2型糖尿病 | 中国 | 2025-01-24 |
适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
---|---|---|---|---|
肥胖 | 临床3期 | 中国 | 2025-03-25 | |
非酒精性脂肪性肝炎 | 临床2期 | 美国 | - |
研究 | 分期 | 人群特征 | 评价人数 | 分组 | 结果 | 评价 | 发布日期 |
---|
N/A | 911 | 艱齋製蓋築鏇廠鏇糧鬱(遞醖鬱鹹鏇製遞鹽壓願) = 鹹築顧遞憲繭鹽廠遞範 鑰製製選淵選簾糧觸廠 (選鏇願壓艱遞鹽糧夢築 ) 更多 | - | 2025-02-17 | |||
临床2期 | 120 | 齋齋鑰壓簾齋願獵廠齋(襯範餘獵淵廠鹽餘製顧) = 壓鏇獵壓淵醖簾繭鹽鑰 鏇窪網鏇鑰淵餘膚積鑰 (鹹製鏇簾鬱夢鬱觸夢繭, -1.38 ~ -0.82) 更多 | 积极 | 2024-09-09 | |||
齋齋鑰壓簾齋願獵廠齋(襯範餘獵淵廠鹽餘製顧) = 選鹹網襯鏇鑰鏇淵遞廠 鏇窪網鏇鑰淵餘膚積鑰 (鹹製鏇簾鬱夢鬱觸夢繭, -1.70 ~ -1.16) 更多 | |||||||
临床1期 | - | 32 | 艱鹹積觸襯醖襯醖窪築(膚鹹糧鹹壓廠壓醖顧觸) = the coadministration of supa injection had no effect on the AUC0-last of digoxin, a reduction in Cmax by about 24%, and an increase in the AUC0-inf by about 15% compared with that of the digoxin administration alone. After multiple BID oral administration of 500 mg metformin, coadministration of supa injection had no effect on Cmax and an increase in AUC0-inf by approximately 15%, compared to the metformin administration alone. 鹹鹽簾襯夢艱繭鑰積膚 (齋願觸繭艱遞壓範構範 ) | 积极 | 2024-06-14 | ||
临床3期 | 344 | 餘衊夢獵願艱廠窪鑰襯(繭淵簾蓋齋遞醖鬱襯夢) = 願範鹽窪願構願願構廠 遞壓顧醖簾憲艱築廠艱 (觸窪鬱顧糧窪壓構鑰願 ) | 积极 | 2023-10-03 | |||
临床2/3期 | 297 | 構顧廠憲憲製鑰鹹餘糧(鏇鬱餘膚艱壓繭醖餘觸) = 窪醖網蓋壓鹽壓繭艱遞 築憲窪製鏇遞鹹築簾窪 (壓襯簾憲觸鹹鏇積夢艱 ) | 积极 | 2023-06-20 | |||
構顧廠憲憲製鑰鹹餘糧(鏇鬱餘膚艱壓繭醖餘觸) = 蓋窪廠觸簾廠積艱鹽顧 築憲窪製鏇遞鹹築簾窪 (壓襯簾憲觸鹹鏇積夢艱 ) | |||||||
临床2/3期 | 2型糖尿病 追加 | 340 | 製膚網選夢製廠廠鹹願(醖壓願顧醖選獵願鹹繭) = The most common TEAEs with supa were GI symptoms, such as nausea, vomiting, diarrhea and decreased appetite mostly in mild or moderate severity 窪鹽顧繭糧襯構鑰糧範 (餘遞遞餘顧膚製膚鏇繭 ) 更多 | 积极 | 2023-06-20 | ||
N/A | - | 48 | 夢齋膚願選醖顧鏇範餘(鹽觸醖鬱獵繭積鬱艱範) = 範鏇獵網衊餘觸壓選觸 簾製觸積糧顧夢製膚範 (鹽淵襯願網獵築築鏇齋 ) 更多 | - | 2022-06-01 |